Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 1;30(10):1622-1629.
doi: 10.1093/annonc/mdz287.

Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer

Affiliations

Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer

R Dienstmann et al. Ann Oncol. .

Abstract

Background: It remains unknown to what extent consensus molecular subtype (CMS) groups and immune-stromal infiltration patterns improve our ability to predict outcomes over tumor-node-metastasis (TNM) staging and microsatellite instability (MSI) status in early-stage colorectal cancer (CRC).

Patients and methods: We carried out a comprehensive retrospective biomarker analysis of prognostic markers in adjuvant chemotherapy-untreated (N = 1656) and treated (N = 980), stage II (N = 1799) and III (N = 837) CRCs. We defined CMS scores and estimated CD8+ cytotoxic lymphocytes (CytoLym) and cancer-associated fibroblasts (CAF) infiltration scores from bulk tumor tissue transcriptomes (CMSclassifier and MCPcounter R packages); constructed a stratified multivariable Cox model for disease-free survival (DFS); and calculated the relative proportion of explained variation by each marker (clinicopathological [ClinPath], genomics [Gen: MSI, BRAF and KRAS mutations], CMS scores [CMS] and microenvironment cells [MicroCells: CytoLym+CAF]).

Results: In multivariable models, only ClinPath and MicroCells remained significant prognostic factors, with both CytoLym and CAF infiltration scores improving survival prediction beyond other markers. The explained variation for DFS models of ClinPath, MicroCells, Gen markers and CMS4 scores was 77%, 14%, 5.3% and 3.7%, respectively, in stage II; and 55.9%, 35.1%, 4.1% and 0.9%, respectively, in stage III. Patients whose tumors were CytoLym high/CAF low had better DFS than other strata [HR=0.71 (0.6-0.9); P = 0.004]. Microsatellite stable tumors had the strongest signal for improved outcomes with CytoLym high scores (interaction P = 0.04) and the poor prognosis linked to high CAF scores was limited to stage III disease (interaction P = 0.04).

Conclusions: Our results confirm that tumor microenvironment infiltration patterns represent potent determinants of the risk for distant dissemination in early-stage CRC. Multivariable models suggest that the prognostic value of MSI and CMS groups is largely explained by CytoLym and CAF infiltration patterns.

Keywords: CMS; colorectal cancer; immune; microsatellite instability; prognosis; stromal.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Adjusted disease-free survival (DFS) Kaplan−Meier curves stratified by CytoLym and CAF groups, estimated with multivariable Cox proportional hazard model controlling for pT, pN, age, sex, primary tumor location, MSI status and CMS4 scores:chemotherapy untreated (A), chemotherapy treated (B), stage II (C) and stage III (D) CRC cohorts.
Figure 2.
Figure 2.
Relative proportion of explained variation in disease-free survival (DFS) of the full multivariable model in chemotherapy untreated (A), chemotherapy treated (B), stage II (C) and stage III (D) CRC cohorts.

Similar articles

Cited by

References

    1. Siegel R, Miller KD, Fedewa SA. et al. Colorectal cancer statistics, 2017. CA Cancer J Clin 2017; 64: 177–193. - PubMed
    1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J. et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49(6): 1374–1403. - PubMed
    1. Dienstmann R, Salazar R, Tabernero J.. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J Clin Oncol 2015; 33(16): 1787–1796. - PubMed
    1. Dienstmann R, Mason MJ, Sinicrope FA. et al. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Ann Oncol 2017; 28(5): 1023–1031. - PMC - PubMed
    1. Mlecnik B, Bindea G, Kirilovsky A. et al. The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med 2016; 8(327): 327ra26. - PubMed

Publication types

MeSH terms

Substances